Treatment Information

Back

Ovarian Cancer treatment details. Biologic therapy.

Seidman Cancer Center, Cleveland, OH, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Cleveland, OH
Treatments:Biologic therapyHospital:Seidman Cancer Center
Drugs:Journal:Link
Date:Mar 2014

Description:

Patients:
This phase 2 study involved women with recurrent platinum-sensitive epithelial ovarian, peritoneal, or fallopian tube cancer who were divided into two separate treatment groups. Group A had 14 patients with an average age of 62 years, while group B had 28 patients with an average age of 62 years.

Treatment:
Patients in group A were treated with the biologic therapy agent sorafenib.

Patients in group B were treated with the biologic therapy agent sorafenib and the chemotherapy agents carboplatin and paclitaxel.

Toxicities:
The most severe toxicities in group A were of grade 3 and included rash, abdominal pain, and fatigue.

The most severe toxicities in group B were grade 4 infusion-related reaction. Grade 3 hand-foot skin reaction, vomiting, and nerve toxicity were also reported.

Results:
The median overall survival rates for groups A and B were 25.6 and 25.9 months, respectively.

Correspondence: Dr. Steven Waggoner; email: [email protected]



Back